Nu Skin Enterprises, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nu Skin Enterprises, Inc.
Health And Wellness On Capitol Hill: Monograph Reform, Wyden On CBD Rule, OTC Daily Contraceptive Access
Energy and Commerce members try again on monograph; Democrats want to ensure OTC oral contraceptive access; Wyden asks for faster CBD rulemaking at FDA; and House passes FDA's FY 2020 funding.
Legal dispute between FDA and Pharmanex decided in 1999 could be precedent for using hemp-derived ingredients including CBD in supplements, even though CBD already has been authorized for clinical drug evaluation and for use in a drug, says attorney Miriam Guggenheim.
With the release of an atypically lean, clean FDA user-fee reauthorization draft bill, it’s doubtful that cosmetics regulatory reform language will get tacked onto the must-pass legislation. Stakeholders likely will refocus their efforts on standalone cosmetics legislation to modernize FDA’s oversight of the industry.
Herbalife is the focus of a Securities and Exchange Commission investigation into anti-corruption compliance in the firm’s China business, the company reported in a Jan. 20 regulatory filing. An analyst covering the stock believes the investigation will have little impact on growth.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.